KREBS BIOCHEMICALS & INDUSTRIES
|
|
BOM : 524518     NSE : KREBSBIO     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Jan 23,2025 |
Price(EOD): ₹ 101.98
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 220.28 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KREBS BIOCHEMICALS & INDUSTRIES | 13.9% | -0% | 23.6% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 0.9% | 34.7% |
CIPLA | 0.6% | -1.7% | 8.4% |
DR REDDYS LABORATORIES | -1.6% | -4.6% | 14.3% |
ZYDUS LIFESCIENCES | -0.5% | 2.5% | 36% |
DIVIS LABORATORIES | -1.1% | 1.1% | 57.7% |
MANKIND PHARMA | 1.3% | -9.5% | 16.6% |
TORRENT PHARMACEUTICALS | 2.8% | -4% | 28.6% |
LUPIN | 1.8% | -0.8% | 49.6% |
FUNDAMENTAL ANALYSIS OF KREBS BIOCHEMICALS & INDUSTRIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KREBS BIOCHEMICALS & INDUSTRIES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-10.11
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -21.76 Cr
[Latest Qtr - Sep2024 - Standalone Results ] -1.84
P/B Calculated based on Book Value of Rs -119.22 Cr
[Latest Year - Mar2024 - Standalone Results ] 4.34
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -11% -21% |
SHARE PRICE MOMENTUM OF KREBS BIOCHEMICALS & INDUSTRIES
KREBS BIOCHEMICALS & INDUSTRIES vs SENSEX
DEBT OF KREBS BIOCHEMICALS & INDUSTRIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
-1.62 -1.84 -1.91 -1.79 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KREBS BIOCHEMICALS & INDUSTRIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KREBS BIOCHEMICALS & INDUSTRIES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-0.26% -23.41% -11.41% -11.41% |
-13.67% -200.78% -61.28% -61.28% |
QtrlyTrend |
-8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
KREBS BIOCHEMICALS & INDUSTRIES related INDICES
You may also like the below Video Courses
FAQ about KREBS BIOCHEMICALS & INDUSTRIES
Is KREBS BIOCHEMICALS & INDUSTRIES good for long term investment?
As on Jan 23,2025, the Fundamentals of KREBS BIOCHEMICALS & INDUSTRIES look Poor and hence it may not be good for long term investment ! See Financial Performance of KREBS BIOCHEMICALS & INDUSTRIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KREBS BIOCHEMICALS & INDUSTRIES UnderValued or OverValued?
As on Jan 23,2025, KREBS BIOCHEMICALS & INDUSTRIES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES ?
As on Jan 23,2025, the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES is Rs. 122.36 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -108.18
Fair Value [Median EV / Sales Model] : Rs. 114.81
Fair Value [Median Price / Sales Model] : Rs. 129.91
Estimated Median Fair Value of KREBS BIOCHEMICALS & INDUSTRIES : Rs. 122.36
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.